|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-10-11
|
|
pubmed:abstractText |
Gefitinib ('Iressa', ZD1839), an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), has shown antitumor activity in refractory patients with non-small-cell lung cancer (NSCLC) in clinical trials. We have retrospectively analyzed the efficacy and tolerability of gefitinib in patients with advanced NSCLC treated at Okayama University Hospital.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0169-5002
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
255-61
|
|
pubmed:meshHeading |
pubmed-meshheading:15474674-Adult,
pubmed-meshheading:15474674-Age Factors,
pubmed-meshheading:15474674-Aged,
pubmed-meshheading:15474674-Aged, 80 and over,
pubmed-meshheading:15474674-Antineoplastic Agents,
pubmed-meshheading:15474674-Brain Neoplasms,
pubmed-meshheading:15474674-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15474674-Female,
pubmed-meshheading:15474674-Humans,
pubmed-meshheading:15474674-Lung Neoplasms,
pubmed-meshheading:15474674-Male,
pubmed-meshheading:15474674-Middle Aged,
pubmed-meshheading:15474674-Quinazolines,
pubmed-meshheading:15474674-Retrospective Studies,
pubmed-meshheading:15474674-Sex Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
|
|
pubmed:affiliation |
Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. khotta@md.okayama-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
